The Food and Drug administration approved a new Alzheimer's drug today that promises to modestly slow cognitive decline. With millions of Americans suffering from Alzheimer's, Kisunla is a treatment that has long been hoped for. But some experts are skeptical about how effective the drug is, and if the potential benefits outweigh the risks.

To tell us more, KCBS Radio's Patti Reising and Bret Burkhart were joined by Dr. Michael Greicius, professor of neurology at Stanford.

 Chinnapong / Getty Images

The Food and Drug administration approved a new Alzheimer's drug today that promises to modestly slow cognitive decline. With millions of Americans suffering from Alzheimer's, Kisunla is a treatment that has long been hoped for. But some experts are skeptical about how effective the drug is, and if the potential benefits outweigh the risks.
To tell us more, KCBS Radio's Patti Reising and Bret Burkhart were joined by Dr. Michael Greicius, professor of neurology at Stanford.
 Chinnapong / Getty Images

KCBS Radio: On-Demand

Today's news from KCBS Radio in the palm of your hand.

Advertisement